Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status.

ABSTRACT:

Background

Phase III, open-label, single-center, controlled study in South Africa (ClinicalTrials.gov: NCT00829010) to evaluate immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in human immunodeficiency virus (HIV)-infected (HIV+), HIV-exposed-uninfected (HEU), and HIV-unexposed-uninfected (HUU) children.

Methods

Children stratified by HIV status received PHiD-CV primary vaccination (age 6/10/14 weeks; coadministered with routine childhood vaccines) and booster dose (age 9-10 months). Immune responses, assessed using enzyme-linked immunosorbent and functional assays, and safety were evaluated up to 14 months post-booster.

Results

Of 83, 101, and 100 children enrolled in H

SUBMITTER: Madhi SA 

PROVIDER: S-EPMC5266190 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature